Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...

From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technology being evaluated. If it is ...

NICE is unable to make a recommendation about the use in the NHS of pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults.

NICE has made 97 positive recommendations for blood cancer treatments over the last decade, five times more than in the previous ten years. 92% of blood cancer treatment recommendations since 2015 ...

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and ...

Olipudase alfa (Xenpozyme, Sanofi) is indicated 'as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in ...

This recommendation is not intended to affect treatment with olipudase alfa that was started in the NHS before this guidance was published. People having treatment outside this recommendation may ...

There is a simple discount patient access scheme for fenfluramine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...